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ABSTRACT
Objective: The main objective of the present study was to develop proniosomal formulations to enhance the oral bioavailability of rosuvastatin 
calcium by improving solubility, dissolution, and/or intestinal permeability.
Methods: Proniosomal powder formulations were prepared with rosuvastatin calcium drug varying the Span 40 and cholesterol ratio in the range 
of 0.8:0.2–0.2:0.8 using maltodextrin as carrier by slurry method. The prepared proniosomal powder was filled into capsules. The bioavailability 
enhancement of proniosomes loaded with drug was studied focusing on non-ionic surfactants composition and drug:Span 40 ratio. Prepared 
proniosomes were characterized for their particle size distribution, zeta potential, entrapment efficiency, in vitro dissolution study, and thermal 
characteristics to understand the phase transition behavior. Further, the formulated proniosomes were subjected to stability behavior, ex vivo 
permeation studies using rat intestine followed by in vivo studies.
Results: Physicochemical studies help in optimization of formulations. Enhancement in dissolution is due to incorporation of rosuvastatin calcium 
into the non-ionic surfactant and change in the physical state from crystalline to amorphous, thus improving oral bioavailability. Ex vivo studies show 
significant permeation enhancement across gastrointestinal membrane compared to control.
Conclusion: Proniosomes provide a powerful and functional way of distribution of inadequately soluble rosuvastatin calcium drug which is proved 
from in vivo studies based on the enhanced oral delivery.
Keywords: Proniosomes, Niosomes, Permeability, Pharmacokinetics, Bioavailability.
INTRODUCTION
The conventional techniques of improving the bioavailability act by 
enhancing the dissolution behavior [1] such as reducing the particle 
size by cogrinding technique [2], in situ crystallization [3], spray drying 
technique [4] but cannot preclude or alter the gastrointestinal tract 
barrier function and pre-systemic metabolism along with particulate 
aggregates formation, and toxicity from vehicles [5,6].
Hence to overcome all such difficulties encapsulation of the drug in 
vesicular structures [7] in the form of pharmacosomes, liposomes [8], 
niosomes [9], and cubosomes which can be expected to prolong the 
duration of the drug in systemic circulation, and reduce the toxicity 
by selective uptake along with lymphatic transport thus leading to 
improved permeation [10] along with rate and extent of absorption 
by avoidance of first pass metabolism [11]. Niosomes [12] which are 
comparatively stable chemically and cheap in price face physicostability 
problems, namely, sedimentation of particles, leading to fusion and 
aggregation and also leakage of drug on storage.
To improve the stability of vesicular systems [13], provesicular 
system [14] was introduced without altering or affecting intrinsic 
properties of the drugs entrapped. Proniosomes [15-17] are defined 
as vesicles composed of actively drug with readily aqueous soluble 
carrier that is coated with surfactant (non-ionic) to form dry, free-
flowing product. Thus, on contact with sterilized water, niosomes are 
generated. With benefits of firmness during sterilization, measuring, 
transfer, distribution, and storage proniosomes became a versatile 
system for delivery of numerous drugs [18,19].
Rosuvastatin calcium and hydroxy-3-methylglutaryl coenzyme 
A reductase are a dyslipidemic agent used in the treatment of 
hypercholesterolemia [20] and for the management of coronary artery 
disease [21-23]. Rosuvastatin peak plasma concentrations are reached 
in 3–5 h, the absolute bioavailability is approximately 20% with poor 
water solubility and a mean plasma elimination half-life of 19 h [24]. 
To the best of our knowledge, no articles are available in literature on 
proniosomes of rosuvastatin calcium and henceforth an attempt was 
made to formulate and evaluate the same.
The rationale and novelty of the study are about developing a more 
stable proniosome dosage form then delivering it into body thorough 
oral delivery which leads to the generation of niosomes after coming 
in contact with biological fluids. Subsequently, the existing difficulty 
of poor absorption and bioavailability related to low solubility for the 
drug rosuvastatin calcium is overcome by formulating a novel drug 
delivery system in the form of proniosomes.
METHODS
Animal studies for both ex vivo and in vivo experiments were conducted 
at Albino research center (Registration No. 1722/RO/Ere/S/13/
CPCSEA) with prior approval of the Institutional Animal Ethical 
Committee. Euthanasia and disposal of carcass were in accordance with 
the guidelines.
Rosuvastatin calcium was a kind gift sample from MSN Labs, Hyderabad, 
India. Span and cholesterol (>99%) procured from Sigma, St. Louis, 
Missouri, United States of America. Maltodextrin was a generous gift 
sample from Dr. Reddy’s Laboratories, Hyderabad. All other chemicals 
were of analytical grade and solvents were of high-performance liquid 
chromatography (HPLC) grade. Freshly collected double-distilled water 
was used all through the experiment.
© 2020 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2020.v13i12.39585
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Formulation of proniosomes
Essential components of proniosomes used in the formulation are non-
ionic surfactants acting as permeability enhancers, carrier or coating 
material, and membrane stabilizers. Among the carriers, maltodextrin 
and sorbitol are available in the preparation of proniosomes. 
Maltodextrin usage as carrier in preparation of proniosomes permits 
stretchability in the incorporation of surfactant and other ingredients 
at various ratios. Sorbitol usage results in the formation of mass that is 
like solid cake [25]. Non-hygroscopicity and compatibility with drugs 
are added advantages with maltodextrin. Finally, efficient rehydration 
is the outcome when the surfactant is coated as thin coat which is made 
possible by maltodextrin because of its high surface area and preserved 
morphology [26].
The maximum benefit of proniosomes systems can be achieved when it 
forms stable niosomes with high entrapment efficiency after hydration 
in the gastric fluids. Cholesterol and structural lipid help in accentuating 
the entrapment of drugs preventing it leakage by stabilizing the 
bilayered membrane. Although lecithin is other alternative for 
cholesterol as membrane stabilizer, lecithin is not widely used as it 
imparts lesser stability when measured against cholesterol [25].
Proniosomes were prepared varying the non-ionic surfactant and 
cholesterol ratios in the range of 0.8:0.2–0.2:0.8 using maltodextrin as 
carrier assigning the codes for various formulations. All surfactants used 
were in excess of their critical micelle concentrations. In the present 
invention among spraying method, coacervation phase separation 
method, and slurry method for the preparation of proniosomes; 
slurry technique or process [25] is adapted and the composition is 
represented (Table 1).
Evaluation/characterization of proniosomes
Hydration of proniosomal systems
Hydration of proniosomal systems is judged by studying the form, 
shape and structure of the niosomes formed from the proniosomes 
by optical microscopy (Olympus-CH20i). Procedure involves addition 
of small or little quantities of water onto a cavity glass slide where 
the proniosome powder was taken. Under an optical microscope, the 
formation of niosomes was monitored and photomicrograph was taken.
Measurement of micromeritic properties of proniosomal systems
Micromeritic properties are assessed by flow properties of powder 
which are vital in handling and processing operations and for further 
dosage form development. Flow properties are reviewed from angle of 
repose [27] studied by fixed funnel technique [28]. Briefly, proniosome 
powder was poured into a funnel which was fixed at a position so that the 
13 mm outlet orifice of the funnel is 10 cm above a level black surface. The 
powder flowed down from the funnel to form a cone on the surface, and 
the angle of repose was then calculated by measuring the height of the 
cone and the diameter of its base. And also, Carr’s index and Hausner’s 
ratio are obtained from bulk and tapped density calculations [29].
Determination of size of niosomes, zeta potential, entrapment efficiency, 
and number of niosomes
For quantifying these parameters, proniosome powders are to be 
converted into niosome dispersions, which are obtained by hydration 
followed by 3 min bath sonication (Soltec 2200 MH, India). For the 
formed niosomes, average size and its distribution are checked by 
Nanoparticle Analyzer (Horiba SZ-100, Japan). The principal behind 
which is spectroscopic technique by photon correlation approach. 
Smoluchowski equation method is used to check zeta potential [30].
ζ= UEη/ε
Where, “ζ” is zeta potential, “UE” is electrophoretic mobility, “η” is 
viscosity of the medium, and “ε” is dielectric constant.
After suitable dilution of proniosomes with freshly collected double-
distilled water, the samples are proceeded for further analysis. Niosome 
size and polydispersity index (PI) of formed niosomes were obtained 
directly from the nanoparticle analyzer and Zetasizer equipment 
and entrapment efficiency from earlier mentioned and reported 
ultrafiltration technique which was carried out using Centrisart 
(Sartorius AG, Gottingen, Germany) equipment [31]. %Entrapment 
efficiency is obtained by subtracting unentrapped drug from total 
amount of drug.
Provesicular formulations are optimized based on the number of vesicles 
formed after the hydration. The niosomes formed after hydration of 
proniosome powder were counted by optical microscope (Olympus 
CH20i, India) using a hemocytometer, and the number of niosomes per 




Total number of niosomes counted 
Total number of dilution factor 4000
Total number squares countedniosomes per mm³
In vitro dissolution study
In vitro dissolution studies (Lab India DS 8000, India) for proniosome 
powders (filled in capsule dosage form) compared against control (filled 
in capsule dosage form) are performed in USP type-I (basket) apparatus 
containing 900 ml of dissolution medium (pH 6.8 phosphate buffer for 
rosuvastatin calcium) kept at a controlled temperature of 37±0.5°C for 
which the basket speed is set at 50 rpm. Five milliliters sample was 
removed maintaining the sink conditions at definite time points, filtered 
through 0.45 μm Millipore membrane filter before analysis and drug 
release was analyzed by UV–Visible Spectrophotometer (Lab India UV 
3000+, India), determining the absorbance at 241 nm for rosuvastatin 
calcium [32].
Scanning electron microscopy (SEM)
By SEM (Hitachi S-3700N, Japan) technique, morphology of surface 
for both the pure drugs and developed optimized proniosomes was 
identified [33]. Scanning electron microscopic images or pictures are 
taken at an accelerating voltage of 15 keV. On brass, stub samples are 
made to adhere with the help of adhesive tape (double sided), followed 
by slender layer gold coating on sample makes it electrically conductive 
which is prerequisite for observing and taking images.
Transmission electron microscopy (TEM)
TEM (JEOL-100CX-II, Tokyo, Japan) technique also helps in knowing 
the form, shape and structure of samples as in SEM but in more detail. 
Table 1: Composition for rosuvastatin calcium loaded proniosome powder using maltodextrin
Formulation code API (mg) Maltodextrin (mg) Molar ratio (SPAN 40:CHOL) SPAN 40 (mg) CHOL (mg)
RPNS1 10 250 0.8:0.2 80.4 19.3
RPNS2 10 250 0.7:0.3 70.4 28.9
RPNS3 10 250 0.6:0.4 60.3 38.6
RPNS4 10 250 0.5:0.5 50.3 48.2
RPNS5 10 250 0.4:0.6 40.2 57.9
RPNS6 10 250 0.3:0.7 30.2 67.5
RPNS7 10 250 0.2:0.8 20.1 77.2
API: Active Pharmaceutical Ingredient: Rosuvastatin calcium; CHOL: Cholesterol
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Before observation of samples, on a copper grid (coated with carbon) 
sample, lean film is to be negatively stained using 0.2% w/v solution of 
sodium phosphotungstate left for air drying followed by imaging [34].
Differential scanning calorimetry (DSC)
DSC (Shimadzu 60H, Tokyo) analysis of optimized formulation 
and pure drug is studied for the molecular state of the compound. 
DSC curves help in deducing heat of fusion and melting point. 
Approximately 5±2 mg of sample is taken in a sealed pan (hermitically) 
made of aluminum and gradually exposed to temperature at 
10°C min-1  heating rate from 20 to 300°C under gas (Nitrogen) flow 
at a constant rate of 30 ml.min-1.
Powder X-ray diffractometry (PXRD)
The PXRD (Shimadzu 7000, Tokyo) repeated format for both drugs and 
most effective powder formulations is received at a voltage of 45 kV; 
when a beam of Cu Kα radiation, generated from 40 mA current moves 
forward through Ni filtered monochromator made up of graphite onto 
detector. All samples were run at 1° (2 θ) min-1 from 3° to 45° (2 θ).
Fourier-transform infrared (FT-IR) spectroscopy 
IR spectra of drug, best powder formulation, and excipients such as 
maltodextrin are acquired from FT-IR spectrophotometer (Shimadzu 
8400S, Japan) at a scanning range of 4000–400 cm-1 with a resolution of 
4 cm-1 to study the drug-excipient interactions. The sample for which is 
prepared following potassium bromide (KBr pellet) procedure.
Stability studies
Stability for the best formulations is studied for a period of 180 days 
for various parameters such as particle size of niosomes formed from 
proniosomes, percentage retention of drug, and ex vivo permeation 
across rat intestine. At predetermined time points, that is, 0, 30, 60, 90, 
120, and 180 days, samples kept at 24±2°C and 4±2°C in aluminum foil 
covered glass vials are taken out hydrated, looked for crystal formation 
of drug under microscope (optical) and also for above-mentioned 
parameters.
Ex vivo absorption study using rat intestine
The study was conducted at albino research center (Registration No. 
1722/RO/Ere/S/13/CPCSEA) with prior approval of the Institutional 
Animal Ethical Committee. Euthanasia and disposal of carcass 
were in accordance with the guidelines. Albino Wistar rats (male) 
approximately weighing 200 g are taken. The animals were housed 
in separate cages in a clean room and maintained under controlled 
condition of temperature and the rats had free access to food and 
water. Before ex vivo absorption study experiments, the rats fasted 
overnight with free access to water were sacrificed by ether inhalation 
technique. An incision was made through a midline to expose the 
abdominal content. Ten centimeters of small intestine (ileum) segment 
used for study were collected and flushed with freshly prepared Krebs 
Ringer solution to clean intestine so that it is free from mucus and all 
adhered contents. Into the ileum which was tightly closed at one end, 
proniosome dispersion (0.5% w/v PEG200) equivalent to 2 mg of 
drug was introduced and further closed tightly on another end. The 
tissue was immersed into a continuously aerated organ bath further 
into receptor compartment consisting of 250 ml of phosphate buffer 
(pH 6.8) maintained at 37±0.5°C. Five milliliters sample was withdrawn 
at definite time intervals and sink conditions are maintained and are 
further analyzed. Control (drug dispersion equivalent to 2 mg) and 
proniosomal systems are compared [35]. The cumulative amount of 
drug permeated was plotted against time. The steady-state flux was 
calculated from the slope of linear portion of the cumulative amount 
permeated per unit area versus time plot. The enhancement ratio was 
calculated by dividing flux of formulation with flux of control.
In vivo bioavailability studies
HPLC (Waters separation module – Model No: 2690; Detector: PDA 
– Model No: 2996, USA) method is developed and validated for the 
estimation of respective sample drug in serum [36].
Sample analysis
Rosuvastatin calcium was quantitatively determined in serum by HPLC 
using 45:55 (v/v) orthophosphoric acid and acetonitrile, respectively, 
as mobile phase at a flow rate of 1.0 ml/min equipped with LC-10 
AT solvent delivery unit. A C8 reverse-phase stainless steel analytical 
column (250 mm×4.6 mm) with 5 μm particle size was employed 
for chromatographic separation (Kromasil). The column eluent was 
monitored at a wavelength of 241 nm using a PDA detector, and the 
sensitivity was set at 0.005 AUFS at ambient temperature. The serum 
samples were processed by protein precipitation method. Briefly, 100 μl 
of serum sample was treated with 100 μl of internal standard (1 μg/ml 
of atorvastatin in methanol) and vortexed (Remi Equipments, India) 
for 1 min. The drug was extracted with 0.2 ml of acetonitrile, vortexed 
for 10 min followed by centrifugation at 4000 rpm for 15 min and the 
separated organic layer was injected onto the HPLC (20 μl). The limit of 
detection and quantification were 10 and 30 ng/ml, respectively. The 
concentration versus peak area ratio plot was linear (r2>0.9922) over 
the concentration range of interest (standard preparation), and the 
rosuvastatin calcium content in samples was quantified using this plot.
Pharmacokinetic study
The study was conducted at albino research center (Registration No. 
1722/RO/Ere/S/13/CPCSEA) with prior approval from the Institutional 
Animal Ethical Committee. Albino Wistar rats (male) approximately 
weighing 200 g are selected for these investigations which are fasted 
for overnight. These Wistar rats are split up into two groups with six 
in every group and delivered with each treatment at a random basis. 
Two groups include one for control (pure drug – oral suspension) 
and one for optimized proniosome formulation. Accurately weighed 
dose of 10 mg/kg body weight the drug or optimized formulation is 
administered. Two hundred and fifty microliters of blood sample are 
taken or withdrawn into microcentrifuge tubes retro-orbital plexus at 
definite time points. Serum was obtained from the collected blood which 
was left to clot by centrifugation process for about 10 min at 10,000 rpm 
using centrifuge (Remi R-24, India). Thus, obtained drug containing 
serum is stored at a temperature of −20°C until further analysis.
Calculation of pharmacokinetic parameters
Cmax and Tmax are picked up from the graph plotted between 
concentrations of drug in serum at various time points. Trapezoidal rule 
technique is followed to determine area under the curve (AUC)0–t. In the 
same way, AUCt–∞ was calculated by dividing concentration of drug at 
last time point in the serum with Ke. The relative bioavailability (RA) 
was estimated by dividing the AUC0–∞ of proniosome formulation with 
control oral suspension.
Statistical analysis
The data obtained were subjected to Student’s “t”-test and one-way 
analysis of variance (ANOVA), and the significance of difference between 
formulations was calculated by Student–Newman–Keuls (compare all 
pairs) with InStat GraphPad Prism software (version 4.00; GraphPad 
Software, San Diego, California). The level of statistical significance was 
chosen as p<0.05.
Ex vivo/in vivo correlation
Ex vivo/in vivo correlation was performed by determining the r2 
value from the graph plotted between the AUC of in vivo and ex vivo 
concentration at different time points [37].
RESULTS AND DISCUSSION
Preparation of proniosome powders
In the present study, proniosomes are formulated, developed, and 
assessed for their scope in raising the quality of the delivery of 
rosuvastatin calcium drugs by oral route. Accurately weighed amounts 
using weighing balance (sartorius TE 124S, Germany) for mixture 
(250 μmol) containing different types of Spans and cholesterol at 
diversified molar ratios (0.8:0.2, 0.7:0.3, 0.6:0.4, 0.5:0.5, 0.4:0.6, 
0.3:0.7, and 0.2:0.8) and active component or ingredient (10 mg) were 
solubilized in 20 ml of chloroform and methanol (2:1). The formed 
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mixture was shifted into 250 ml flask with round bottom and upon 
addition of maltodextrin (250 mg) slurry was formed. The round 
bottomed flask was connected to a rotary vacuum evaporator (Rotavap 
PBU-6, India) to remove organic solvent by evaporation process at low 
pressure and 45±2°C temperature with 60–70 rpm. Complete removal 
of organic solvent, results in dry product and leaving it in a vacuum 
oven at 24°C for a night further make the product free flowing. Thus, 
acquired proniosome powders are kept in glass vial at 4°C which can be 
delivered in the form of capsules. For comparison, control formulation 
devoid of Spans and cholesterol was processed.
Niosomes are formed from proniosomes immediately on contact with 
water at in vitro conditions or with body fluids at in vivo conditions 
which is considered to be achieved without great effort when compared 
with traditional technique of preparation of niosomes by dry-film 
procedure as plan of work involves tedious shaking process to absorb 
water by surfactants. Thus, the production from proniosomes is 
considered as the greatest advantage, that is, eases of use.
Evaluation/characterization of proniosomes
Evaluation of proniosomes after preparation aids in characterizing the 
formulation and identifying the optimized formulation [38-40].
Hydration of proniosome systems
On hydration of proniosomes, niosomes were derived and were formed 
immediately on contact with water. The photomicrographic images are 
shown (Fig. 1) at different magnifications.
Measurement of micromeritic properties of proniosome systems
The measurement of flow properties of the proniosome powders plays 
a key role as values help in various operations during manufacturing 
of a dosage form such as ease with which the powders are filled into 
the container and uniformity of the dose. Angle of repose, Carr’s 
compressibility index, and Hausner’s ratio results help in evaluating 
flow measurements. Cohesion or internal friction between the 
particles is dependent on the angle of repose values which are directly 
proportional to each other. Therefore, smaller the angle of repose 
values (<26°) better will be the flow properties. This is strengthened by 
Carr’s compressibility index values which are <17 and Hausner’s ratio 
which are <1.23 [27] and the results are indicated (Table 2).
Determination of Size of niosomes, zeta potential, entrapment 
efficiency, and number of niosomes
Determination of size of the niosomes and size distribution of niosomes 
formed is significant [41]. The average niosomes size was in between 
180 and 220 nm. Concentration of the cholesterol and length of the 
surfactant alkyl chain influences the size of the niosomes. Longer the 
chain length, smaller the size of niosomes.
The particle size increased because of increase in the width of lipid 
bilayers, when cholesterol concentration increases to have positive 
effect on the bilayer characteristics such as rigidness and hydrophobicity.
The PI values are inside the allowable limits for all the proniosomal 
formulations, indicating enhanced homogeneity which is to judge 
unimodal size distribution. The lower the polydispersity index 
value, the more monodispersed the dispersion which is <1 for all the 
proniosomal formulations.
A zeta potential value for all proniosomal formulations was between 
−48.2 and +54.4 mV.
Ultrafiltration procedure is employed to determine the amount of 
drug entrapped as the procedure does not involve any dilution levels 
as in chromatographic techniques, that is, column and dialysis. Very 
high encapsulation efficiency results were exhibited for niosomes 
prepared from Spans which is based on the following explanation, that 
is, the more the lipophilic part of drug molecule, the better the drug 
accommodation would be.
Entrapment efficiency for all proniosomal formulations is in the range 
of 77% and 89% whose values are directly proportional to cholesterol 
concentration. Better the values, lesser the drug leakage from the rigid 
and compact stable bilayers due to increased hydrophobic interactions. 
However, extremely high content of cholesterol leads to decrease in 
entrapment of drug within niosomes which is because of disruption of 
rigid hydrophobic bilayers.
Spans 20 and 80 have low-phase transition temperature, thus leading to 
bilayers which are low in permeation compared to Span 60 [42]. Phase 
transition temperature and availability of lipophilic ambience also play 
major role in entrapment efficiency. Span 40 and Span 60 which are solids 
in normal room temperature have relatively elevated phase transition 
temperatures hence highest drug entrapment. The lower entrapment of 
drug when Span 80 with unsaturated alkyl chain is used though it has 
same head group as Span 60 is because of the presence of double bond in 
the chemical structure unlike Span 60. Same kind of pattern is followed 
by Tween 80 among other tweens (20, 40, and 60) which fortifies the 
fact that tendency toward aqueous and non-aqueous phase plays an 
important part in release of the drug. Proniosome formulations prepared 
using Tween 20, 40, 60, and 80 showed relatively low drug encapsulation 
against prepared using Spans, which is due to insufficient amount of 
cholesterol, that is, vesicles are obtained only when the cholesterol content 
is above 33.33 mol% [43]. Amount of cholesterol directly influences the 
encapsulation of the drug with reverse action on vesicle size.
The more the number of niosomes formed from proniosomes in the 
GI tract on hydration, the better the dosage form can be speculated. 
Among various formulations, the formulation with following code 
RPNS3 demonstrates good number of niosomes. The results of all above-
mentioned physicochemical parameters are represented (Table 3) for 
various proniosomal formulations.
In vitro dissolution study
The percentage drug release was outstandingly more for almost all 
proniosomal powder formulations when measured against control for 
all proniosomal formulations in the respective dissolution medium. 
The amount of rosuvastatin calcium released from proniosomes was 
between 81% and 94% in 10 min and was remarkably higher compared 
to control (6%).









RPNS1 17.90±0.07 10.40±0.09 1.18±0.01
RPNS2 18.20±0.11 11.30±0.08 1.22±0.26
RPNS3 21.30±0.14 16.20±0.05 1.20±0.06
RPNS4 24.20±0.22 16.40±0.13 1.17±0.13
RPNS5 26.20±0.21 16.80±0.16 1.23±0.16
RPNS6 21.30±0.10 15.50±0.12 1.19±0.18
RPNS7 20.10±0.13 11.30±0.22 1.20±0.13
*Results indicate mean±SD, n=6
Fig. 1: Formation of niosomes from proniosomes under ×10 and 
×450
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Dissolution efficiency of drugs has drastically increased when the 
drug is delivered in the form of proniosomal systems, which might be 
attributed to the improved solubility of drug by non-ionic surfactant 
molecules or transformation of the crystalline state of the drug to 
amorphous state [44]. The data is shown in Table 4.
SEM
SEM images aid in studying the surface morphology of the proniosome 
powders along with drug and carriers. Non-existence of drug crystalline 
structure in proniosome preparations specified the conversion of 
drug to molecular or amorphous state from crystalline form. And also, 
maltodextrin porous structure was not visible in formulations because of 
settling of Spans on the surface of carrier. The images are shown in Fig. 2.
TEM
TEM is a microscopic technique commonly used for the analysis of 
materials on the nanoscale. Because it uses electrons, which have a 
shorter wavelength than light, it is capable of achieving resolution a 
1000 times better than that can be achieved with a light microscope [45].
TEM analysis confirms the spherical shape of niosomes formed after 
hydration of proniosomal systems. The image analysis showed (Fig. 3) 
that the niosomes were surrounded by homogeneous shading, this 
suggests that formed niosomes resembled the drug-enriched core model.
DSC
In DSC thermograph of proniosome formulations, endotherm peak fades 
away or vanishes around melting point which is clearly visible in pure 
drug DSC thermograph, indicating the metamorphosis of crystalline 
state in pure drug to amorphous state in formulations. The DSC images 
of pure drug rosuvastatin calcium and optimized formulation images 
are shown, respectively (Fig. 4a and b).
PXRD
Reduction in the intensity or absence of characteristic drug peaks 
in the proniosome optimized formulations compared to pure drug 
rosuvastatin calcium further confirms the amorphization of the drug by 
PXRD analysis. The PXRD images of pure drug rosuvastatin calcium and 
optimized formulation images are shown, respectively (Fig. 5a and b).
FT-IR analysis
FTIR spectrum of proniosomal formulation without any extra peaks 
when compared to pure drug spectrum extrapolates the lack of 
chemical interaction. IR spectrum of drug, optimized formulation, and 
maltodextrin are shown, respectively (Fig. 6a-c).
Based on the various evaluation parameter results, the optimized 
formulation further proceeded for stability, ex vivo, and in vivo studies.
Stability studies
Shelf life for drug understated conditions is dictated by the amount of 
drug retained within the niosomes. Physical appearance, size of the 
niosomes, percentage retention, and ex vivo permeation across rat 
intestine of respective drugs after storing at 24°C and 4°C temperature 
for 6 months are investigated in the stability studies for optimized 
formulation. Samples were pulled out at specified time points and 
Table 3: Physicochemical characteristics of different proniosomal preparations
Formulation code Particle size* Polydispersity index Zeta potential* % drug entrapped* Number of niosomes/mm3×103
RPNS1 219±12 0.342 49.2±2.6 82.6±1.7 3.09
RPNS2 192±24 0.234 50.9±3.2 77.5±2.4 3.21
RPNS3 180±17 0.136 52.3±3.9 89.5±2.9 3.90
RPNS4 190±19 0.140 48.2±1.9 82.6±1.9 3.76
RPNS5 187±14 0.249 52.1±4.2 83.1±3.4 4.10
RPNS6 214±13 0.256 48.8±4.0 82.2±4.5 3.34
RPNS7 220±23 0.333 54.4±3.9 80.1±3.6 3.51
*Results indicate mean±SD, n=3
Table 4: Dissolution data of rosuvastatin calcium in pure form, and various proniosomal formulations using Span 40
Time (min) Cumulative percentage drug released*
Control RPNS1 RPNS2 RPNS3 RPNS4 RPNS5 RPNS6 RPNS7
5 2.13±0.13 75.32±0.99 76.97±0.93 82.89±0.79 76.74±0.44 75.32±0.19 76.03±0.74 77.68±0.30
10 5.93±0.29 83.79±0.84 87.59±0.24 94.49±0.67 86.64±0.57 81.42±0.57 81.66±0.82 81.19±0.38
20 9.99±0.51 91.83±0.49 89.96±0.79 96.19±0.27 92.33±0.90 85.18±0.39 85.19±0.35 85.67±0.14
30 14.55±0.5 92.81±0.82 93.54±0.64 97.67±0.71 95.20±0.42 91.81±0.44 89.45±0.90 88.27±0.98
45 19.13±0.6 94.74±0.59 97.13±0.41 99.39±0.81 97.38±0.29 94.92±0.64 92.54±0.18 91.12±0.26
60 25.39±0.5 98.09±0.43 99.32±0.30 100.40±0.64 98.15±0.17 96.15±0.24 96.13±0.77 96.12±0.29
*Results indicate mean±SD, n=6
Fig. 2: Scanning electron microscope images of (a) rosuvastatin calcium. (b) Proniosome powder. (c) Maltodextrin
cba
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proniosomal powders were restored to form niosomal dispersions. 
Initially, the powder was found to be dry, free flowing in nature 
without any lumps, after contact with water lead to the formation of 
niosomes immediately. Under optical microscope, drug crystallization 
was also not observed. No change in the size of the particles and size 
distribution represents proniosomal formulation stability. Significantly 
more amount of drug retention was observed at all sampling points. 
And also, ex vivo permeation study results indicated not much variation 
in amount of drug permeated, flux, permeability coefficient, and 
enhancement ratio values when compared to initial. In contrast, the 
formulation was destabilized at room temperature (24°C) resulting in 
larger niosome size, drug leakage with less entrapment efficiency with 
time, and chaotic ex vivo permeation results.
The stability studies suggest that the proniosomal powder was 
comparatively more stable when stored at refrigerated conditions 
(4°C) that at room temperature (24°C) and the results are represented 
(Table 5).
Ex vivo absorption study using rat intestine
Permeation across the gastrointestinal tract is also a rate-limiting 
step for absorption of drug other than dissolution. Therefore, ex vivo 
permeation studies were performed using the rat intestine. Since 
a great number of available active pharmaceutical ingredients get 
absorbed in vivo from the small intestine, it is more relevant to use 
the rat tissue [46]. Hence, we have used ileum portion to evaluate 
the potential of proniosome powder formulations for increasing the 
permeation of drug across the intestine barrier.
The amount of drug permeated from proniosomal systems for 
rosuvastatin calcium has enhanced when compared with respective 
control within a period of 2 h and the results are reported (Fig. 7). The 
flux values also improved for proniosomal system when compared with 
control. The ER above 1 shows enhanced permeation of proniosome 
when compared with control.
Thus, the remarkable improvement in the permeation can be owed to 
the combination of several mechanisms such as presence of non-ionic 
surfactant could obviate the barrier function due to the fluidization of 
the intercellular lipid bilayer, better membrane contact, and permeation 
enhancement property of the non-ionic surfactants might have led to 
altered permeability characteristics of the membrane which otherwise 
result in improved partitioning of the drug into the bilayer and direct 
transfer of niosomes across the epithelial membrane.
In vivo bioavailability study
Pharmacokinetic study
The average serum concentration versus time intervals after orally 
administering optimized formulation of rosuvastatin calcium 
proniosome powder in comparison against control (pure drug at a 
dose of 10 mg/kg) are shown. Various pharmacokinetic parameters are 
calculated and represented (Table 6). Results obtained show a higher 
Cmax and Tmax for proniosomes when compared against control. Slower 
excretion of rosuvastatin calcium drug from proniosomes is evidently 
the reason for higher mean residence time when compared against 
control. AUC values following oral administration are remarkably more 
when compared against control, indicating higher systemic exposure, 
thus overcoming the bioavailability problem, which is raised as a result 
of increased hepatic metabolism. RA for drug after giving proniosomes 
by oral route was found to be more when compared against control 
Table 5: Stability study data of optimized formulation for various parameters
Parameters* Initial 30 days 60 days 90 days 120 days 180 days
Size (nm) 180±17 229±09 239±17 235±12 237±15 224±14
%Retention of drug 89.5±2.9 92.0±3.2 87.0±3.2 91.0±4.1 89.9±3.5 90.9±3.3
Cumulative amount drug permeated (µg/cm2) 248.0±27 254.3±22 259.8±23 267.3±26 255.8±33 249.7±31
*Results indicate mean±SD, n=6
Fig. 3: Transmission electron microscopy images of rosuvastatin 
calcium proniosome powder
Fig. 4: (a) Differential scanning calorimetry (DSC) of pure drug. 
(b) DSC of optimized proniosome formulation (RPNS3)
b
a
Fig. 5: (a) Powder X-ray diffractometry (PXRD) of rosuvastatin 
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with a significant difference of p<0.001. Thus, it is proved from the 
reports that bioavailability of rosuvastatin calcium has been markedly 
improved from proniosomal systems when compared against control. 
The permeability and potential uptake of slightly soluble drugs are 
increased, thus enhancing the bioavailability.
Overall improvement in the RA deduces the potential of proniosomes 
as a suitable carrier for improved oral delivery of rosuvastatin calcium.
Ex vivo/in vivo correlation
The r2 values are closer to linear for optimized formulation of drug when 
graph is plotted between the AUC of in vivo and ex vivo concentration at 
different time points, thus concluding a correlation and is represented 
(Fig. 8).
CONCLUSION
The rosuvastatin calcium proniosomes were prepared by slurry 
method using maltodextrin as carrier at varying ratios of Spans and 
cholesterol. The formulation containing 0.6:0.4 of Span and cholesterol 
was optimized based on the physicochemical characterization and 
dissolution studies. The in vivo pharmacokinetic studies reveal 
potential of proniosomes as suitable carriers for poorly soluble drugs. 
The results of this study clearly indicate the improvement in intestinal 
absorption and oral bioavailability of rosuvastatin calcium. The 
improved delivery of niosome entrapped drug is mediated by vesicle 
adsorption onto the cell surface followed by endocytosis. A particularly 
attractive feature of this study is that it may be applied to preparations 
for oral administration, that is, a proniosome composition may be 
placed inside a capsule which is then swallowed whole. Depending on 
the design of the capsule, the contents will be released somewhere in 
the gastrointestinal tract to form niosomes in vivo. The drug remains 
protected within the layers of the niosomes. It has been suggested that 
protecting a poorly absorbed, labile drug in this manner could help 
absorption. In this connection, it has been noted that niosomes can 
form, irrespective of the ionic strength of the aqueous environment, in 
the range of pH 3.2–8.6. It is assumed that any “free” drug remaining 
in the aqueous environment after spontaneous niosome formation is 
non-toxic and need not be removed. A further in vivo study in humans 
fortifies the improved oral delivery of rosuvastatin calcium before 
human use.
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